Freeline Therapeutics Holdings plc - ADR Stock
Freeline Therapeutics Holdings plc - ADR Stock price
Key metrics
| Market capitalization | $28.24m |
| Enterprise Value | $2.78m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 4.48 |
| P/S ratio (TTM) P/S ratio | 45.55 |
| P/B ratio (TTM) P/B ratio | 0.94 |
| Revenue (TTM) Revenue | $620.00k |
| EBIT (operating result TTM) EBIT | $-67.47m |
Is Freeline Therapeutics Holdings plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Freeline Therapeutics Holdings plc - ADR Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Freeline Therapeutics Holdings plc - ADR:
Analyst Opinions
1 Analyst has issued a forecast Freeline Therapeutics Holdings plc - ADR:
Financial data from Freeline Therapeutics Holdings plc - ADR
| Sep '23 |
+/-
%
|
||
| Revenue | 0.62 0.62 |
-
|
|
| Gross Profit | -0.83 -0.83 |
59%
59%
|
|
| EBITDA | -66 -66 |
39%
39%
|
EBIT (Operating Income) EBIT | -67 -67 |
39%
39%
|
| Net Profit | -50 -50 |
50%
50%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Freeline Therapeutics Holdings plc - ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Freeline Therapeutics Holdings plc - ADR Stock News
Company Profile
Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.
| Head office | United Kingdom |
| CEO | Michael Parini |
| Founded | 2015 |
| Website | www.freeline.life |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
